Business
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Mee...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n\n\n\n Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BORDER-TOP:black 1pt; BORDER-RIGHT:black 1pt; BORDER-BOTTOM:black 1pt; BORDER-LEFT:black 1pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE; BORDER-TOP:1pt black; BORDER-RIGHT:1pt black; BORDER-BOTTOM:1pt black; BORDER-LEFT:1pt black\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n VICTORIA, BC\n \n\n ,\n \n\n Oct. 28, 2024\n \n\n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting two posters at the American College of Gastroenterology (\"ACG\") Annual Scientific Meeting 2024, being held in\n \n Philadelphia, PA\n \n , on October\n \n\n 25-30, 2024.\n \n\n The event is a premier gastrointestinal (\"GI\") clinical meeting and the ACG is a recognized leader in educating GI professionals and the general public about digestive disorders.\n \n\n\n Poster Details:\n \n\n\n\n\n\n\n\n Poster Number:\n \n\n\n\n\n\n P2209\n \n\n\n\n\n\n\n\n Poster Title:\n \n\n\n\n\n\n\n\n Pharmacokinetics and Local Tolerability of EP-104GI, an Extended-Release Formulation of Fluticasone for Treatment of Eosinophilic Esophagitis, after Intra-Esophageal Injection in Mini-Pigs\n \n\n\n\n\n\n\n\n\n\n Session Date & Time:\n \n\n\n\n\n\n Monday, October 28, 2024, 10:30 a.m. – 4:00 p.m. ET\n \n\n\n\n\n\n\n\n Presenter:\n \n\n\n\n\n\n Dr. Amanda Malone\n \n\n\n\n\n\n\n This is a non-clinical poster and received a Presidential Award from the conference, which is a distinction for high quality, novel, unique, and interesting research.\n \n\n\n\n\n\n\n Poster Number:\n \n\n\n\n\n\n P3911\n \n\n...